6541 — Tanvex Biopharma Share Price
0.000.00%
Last trade - 00:00- TWD14.60bn
- TWD15.87bn
- TWD34.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.29 | ||
| Price to Tang. Book | 16.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 419.73 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -56.84% | ||
| Return on Equity | -161.17% | ||
| Operating Margin | -3912.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 0.3 | 5.41 | 22.4 | 61.41 | 34.68 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tanvex BioPharma, Inc. is a holding company. The Company and its subsidiaries are engaged in the research and development of biosimilar products, biological production processes, and the contract development and manufacturing of biological medicines. It excels in areas such as strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and warehousing, sales, and distribution. Its product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), and Perjeta (TX-52). The Company has two subsidiaries, namely Tanvex Biologies Corporation (Tanvex Taiwan) and Tanvex BioPharma USA, Inc. (Tanvex USA). Tanvex Taiwan is responsible for initial stage cell line development and bioprocess development, while Tanvex USA is responsible for further cell line and process development, scaling up the process to achieve commercialization and mass production.
Directors
- Yun Yen CHM
- Helena Makagiansar DGM
- Mike Parker DGM
- Yongjian Wu DGM
- Kaiwen Yang DGM
- Allen Chao DRC
- David Hsia DRC
- Tamon Tseng DRC
- Yuxing Xue DRC
- Jin-Pau Tsai IND
- Taichang Wang IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 8th, 2013
- Public Since
- August 13th, 2015
- No. of Employees
- 133
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 238,610,367
- Address
- Floor 4, Willow House, Cricket Square,, GRAND CAYMAN, KY1-1112
- Web
- https://www.tanvex.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 6541
April 2025 Tanvex BioPharma Inc Corporate Sales Release
Tanvex BioPharma Inc Annual Shareholders Meeting
May 2025 Tanvex BioPharma Inc Corporate Sales Release
Tanvex BioPharma Inc Annual Shareholders Meeting
June 2025 Tanvex BioPharma Inc Corporate Sales Release
July 2025 Tanvex BioPharma Inc Corporate Sales Release
Q2 2025 Tanvex BioPharma Inc Earnings Release
Similar to 6541
Abnova Taiwan
Taiwan Stock Exchange
Applied BioCode
Taiwan Stock Exchange
Energenesis Biomedical Co
Taiwan Stock Exchange
Kim Forest Enterprise Co
Taiwan Stock Exchange
PHARMAESSENTIA
Taiwan Stock Exchange
FAQ
What is the Tanvex Biopharma share price?
As of Today at 23:35 UTC, shares in Tanvex Biopharma are trading at TWD61.00. This share price information is delayed by 15 minutes.
How has the Tanvex Biopharma share price performed this year?
Shares in Tanvex Biopharma last closed at TWD61.00 and the price had moved by +28.42% over the past 365 days. In terms of relative price strength the Tanvex Biopharma share price has outperformed the FTSE Developed Asia Pacific Index by +29.89% over the past year.
What are the analyst and broker recommendations for Tanvex Biopharma?
The overall consensus recommendation for Tanvex Biopharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tanvex Biopharma dividend yield?
Tanvex Biopharma does not currently pay a dividend.
Does Tanvex Biopharma pay a dividend?
Tanvex Biopharma does not currently pay a dividend.
When does Tanvex Biopharma next pay dividends?
Tanvex Biopharma does not currently pay a dividend.
How do I buy Tanvex Biopharma shares?
To buy shares in Tanvex Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tanvex Biopharma?
As of the previous close price of TWD61.00, shares in Tanvex Biopharma had a market capitalisation of TWD14.60bn.
Where are Tanvex Biopharma shares listed?
Here are the trading details for Tanvex Biopharma:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6541
What kind of share is Tanvex Biopharma?
Based on an overall assessment of its quality, value and momentum Tanvex Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tanvex Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Tanvex Biopharma is TWD52.23. That is 14.38% below the last closing price of TWD61.00.
Analysts covering Tanvex Biopharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Tanvex Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tanvex Biopharma. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -2.06%.
As of the last closing price of TWD61.00, shares in Tanvex Biopharma were trading -6.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tanvex Biopharma PE Ratio?
The Tanvex Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD61.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tanvex Biopharma?
Tanvex Biopharma's management team is headed by:
- Yun Yen - CHM
- Helena Makagiansar - DGM
- Mike Parker - DGM
- Yongjian Wu - DGM
- Kaiwen Yang - DGM
- Allen Chao - DRC
- David Hsia - DRC
- Tamon Tseng - DRC
- Yuxing Xue - DRC
- Jin-Pau Tsai - IND
- Taichang Wang - IND